论文部分内容阅读
Pergolide是一种新合成的直接作用于多巴胺能的激动剂.用Pergolide治疗黑质纹状体受损的大鼠证明对恢复鼠的行为的作用比溴隐亭大数倍,在实验性动物巴金森氏病(PD)研究中,其作用较其他麦角类药物长久.本药半衰期长,对治疗患者的开关、起伏现象以及剂末疗效减退都显示有特异的益处.作者用本药治疗22名PD患者,开始每日服0.1mg,逐渐加量直至出现疗效或副作用,最大不超过6mg/日.剂量稳定后出院,每月复查一次,观察1年.全年平均剂量为2.85mg/日.试验结果证明本药对步态失调、姿势固定、肌强直、震颤和运动不能均有明显改善.全年均有效,六个月时疗效最佳.治疗期间左旋多巴和卡别多巴的剂量和服药次数均可减少.原先药物引起的副作用:运动障碍、幻觉、睡眼障碍、恶心、肌张力改变和肌强直,用本药后都得到减轻.由于PD是一种自然进展的神经系统退行性疾病,如果药物能使临床状态长期稳定或阻止其进展,
Pergolide is a newly synthesized agonist that acts directly on dopaminergic. Treatment of nigrostriatal impaired rats with Pergolide proved to be several times more potent at restoring the behavior of rats than bromocriptine, In the study of Parkinson’s disease (PD), its effect is longer than that of other ergot drugs, and the long half-life of the drug has shown specific benefits in terms of switching, fluctuation and end-point curative effect of the treated patients. PD patients, began to take daily 0.1mg, and gradually increase the amount until the efficacy or side effects, the maximum does not exceed 6mg / day. The dose was stable and discharged, monthly review, observed for 1 year. The average annual dose of 2.85mg / day. The test results show that the drug on gait disorders, posture fixation, muscle rigidity, tremor and exercise can not have significantly improved.All year effective, six months, the best effect.During the treatment of levodopa andCadodopa dose And the number of medication can be reduced. The original drug-induced side effects: dyskinesia, hallucinations, sleep disorders, nausea, muscle tone changes and muscle rigidity, are relieved with this drug.Because PD is a natural progression of the nervous system degenerative disease, If the drug can make the clinical status of long-term stability or prevent its progress,